Author

J. Gallon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Approach:statistical model· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

S. Piscuoglio· 4 shared M. A. Rubin· 3 shared C. K. Ng· 2 shared M. Kruithof-de Julio· 2 shared V. Paradiso· 2 shared A. Augspach· 1 shared A. Dahmani· 1 shared A. Ferguson· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

S. Piscuoglio

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Minor intron splicing efficiency increases with the development of lethal prostate cancer

A. Augspach, K. Drake, L. Roma, E. Qian, S. R. Lee, D. Clarke, S. Kumar, M. Jaquet, J. Gallon, M. Bolis, J. Triscott, J. A. Galvan, Y. Chen, G. Thalmann, M. Kruithof-de Julio, , M. A. Rubin

The paper shows that minor intron splicing efficiency increases in castration-resistant prostate cancer and that inhibiting the minor spliceosome reduces tumor burden.

bioRxiv · Dec 9, 2021 · PreprintCancer Biology

Chromatin accessibility changes at intergenic regions associates with ovarian cancer drug resistance

J. Gallon, E. Loomis, E. Curry, N. Martin, L. Brody, I. Garner, R. Brown, J. M. Flanagan

The paper examines chromatin accessibility changes in ovarian cancer cell lines resistant to platinum-based chemotherapy, finding intergenic region alterations linked to drug resistance and Pt-adduct distribution.

bioRxiv · Feb 24, 2021Cancer Biology

Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance

K. A. Cotter, J. Gallon, N. Uebersax, P. Rubin, K. D. Meyer, S. Piscuoglio, S. R. Jaffrey, M. A. Rubin

The paper maps m6A in prostate cancer and shows METTL3-low promotes therapy resistance through upregulated extracellular matrix proteins and hepatocyte nuclear factor-driven gene signatures.

bioRxiv · Jan 12, 2021Cancer Biology

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

G. Bianco, M. Coto Llerena, J. Gallon, S. Taha-Mehlitz, V. Kancherla, M. Konantz, S. Srivatsa, H. Montazeri, F. Panebianco, M. De Menna, V. Paradiso, C. Ercan, A. Dahmani, E. Montaudon, N. Beerenwinkel, , S. Piscuoglio

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

bioRxiv · May 18, 2020Cancer Biology

The Genomic Landscape of Prostate Cancer Brain Metastases

A. Rodriguez, J. Gallon, D. Akhoundova, S. Maletti, A. Ferguson, J. Cyrta, U. Amstutz, A. Garofoli, V. Paradiso, S. Tomlins, E. Hewer, V. Genitsch, A. Fleischmann, E. J. Rushing, R. Grobholz, , M. A. Rubin

This study identifies genomic alterations in prostate cancer brain metastases, highlighting mutations in NF1 and RICTOR and DNA homologous repair defects as potential drivers.

bioRxiv · May 12, 2020 · PreprintCancer Biology